Vect-Horus

Vect-Horus is a private, clinical-stage biotech specializing in overcoming major drug delivery challenges, especially for neurological disorders. Its core technology platform utilizes engineered vectors to shuttle therapeutics across biological barriers like the blood-brain barrier, unlocking new treatment possibilities for CNS conditions and other diseases. The company has established significant validation through strategic partnerships with industry leaders like Ionis Pharmaceuticals and OliX Pharmaceuticals, positioning it as a key enabler in the targeted delivery space. While pre-revenue from product sales, its business model is based on research collaborations and licensing agreements to advance partnered programs.

Proprietary platform of engineered vector molecules (peptides/peptidomimetics) that bind to specific receptors on biological barriers (e.g., blood-brain barrier) to facilitate receptor-mediated transcytosis of conjugated therapeutic or imaging payloads.

Vect-Horus competes in the crowded blood-brain barrier drug delivery space, which includes other peptide/shuttle technologies (e.g., Angiopep, Trojan horse approaches), nanoparticle-based systems, and focused ultrasound. Its differentiation lies in the modularity of its vector platform and its validation through partnerships with leading oligonucleotide therapeutics companies.